Molecular Partners AG ADR MOLN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.85
- Day Range
- $3.72–4.05
- 52-Week Range
- $0.00–5.36
- Bid/Ask
- $3.50 / $4.20
- Shares Outstanding
- 37.51M
- Market Cap
- $147.04M
- Volume/Avg
- 24,540 / 4,441
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 134
Valuation
|
Metric
|
MOLN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.80 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
MOLN
Financial Strength
|
Metric
|
MOLN
|
|---|---|
Quick Ratio | 9.21 |
Current Ratio | 9.42 |
Interest Coverage | −2,959.95 |
Quick Ratio
MOLN
Profitability
|
Metric
|
MOLN
|
|---|---|
Return on Assets (Normalized) | −45.58% |
Return on Equity (Normalized) | −53.96% |
Return on Invested Capital (Normalized) | −53.68% |
Return on Assets
MOLN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Mxxnqhzx | Vpzttw | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mgznpdgb | Jjxbw | $64B | |||
| argenx SE ADR
ARGX
| Gwxrjcblw | Ybhj | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vlgdcwb | Pcvwkzj | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Dcmfgxhz | Fqyml | $24B | |||
| BioNTech SE ADR
BNTX
| Mfrysxs | Lwjd | $23B | |||
| Incyte Corp
INCY
| Frrqwqrxy | Vyjq | $22B | |||
| Moderna Inc
MRNA
| Tpmdsnbxz | Yddqt | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Kwshczyqj | Hwy | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Bpmyflkg | Dzvqm | $13B |
United States